IPMN is a benign neoplasm that grows within the pancreatic duct, and therefore is unlikely to release cfDNA into the blood stream. KRAS mutations are rarely detected in the plasma of patients with benign neoplasms . Since a significant proportion of IPMN cases progress to pancreatic cancer , differentiation of IPMN from pancreatic cancer may have substantial clinical benefits.